Why did Cardinal Health raise its fiscal 2026 EPS outlook?

Management attributes the raise to strong performance and execution across all five operating segments. The new outlook is at least $10.00 non-GAAP diluted EPS, versus the prior $9.65 to $9.85 range. Detailed drivers will be discussed on the February 5, 2026 earnings call.

How significant is the Specialty revenue target?

Cardinal expects Specialty revenues to exceed $50 billion in FY2026, a 16% CAGR over FY24 to FY26 measured from an FY23 baseline. Growth is expected from specialty distribution demand, MSO platform expansion, and BioPharma Solutions, which is projected to grow over 30% in the year.

Did the IRA drug pricing changes disrupt Cardinal's distribution business?

The company says it transitioned manufacturer distribution service agreements for all affected branded pharmaceuticals before the January 1, 2026 effective date. It expects to remain appropriately compensated for its distribution role, though the release does not quantify the financial impact.

Should investors rely on the non-GAAP guidance as a measure of GAAP earnings?

Not directly. Cardinal does not provide GAAP outlook because excluded items such as impairments, acquisition costs, and litigation charges are hard to forecast. Over the past five fiscal years these items moved EPS between $1.79 and $8.44, including a $6.79 goodwill impairment in fiscal 2022, so GAAP results could differ materially from the non-GAAP guidance.

CAH 8-K: Regulation FD — Jan 13, 2026

01—Abstract

Summary

Summary of the 8-K filed January 13, 2026. Cited figures are marked; the original filing is the authoritative source.

Cardinal Health (NYSE: CAH) issued a Regulation FD press release on January 13, 2026, ahead of its appearance at the 44th Annual J.P.

Morgan Healthcare Conference. The headline item is an upward revision to fiscal year 2026 non-GAAP diluted EPS guidance to at least $10.00^a, up from the prior range of $9.65 to $9.85. Management attributes the raise to strong performance and execution across its five operating segments, and it will provide further detail on its February 5, 2026 second-quarter earnings call.

The company also reiterated growth ambitions in Specialty, now expecting over $50 billion^b of Specialty revenue in FY2026, a 16% three-year CAGR (FY24 to FY26, measured from an FY23 baseline). Management cited specialty distribution demand, expansion of its MSO platforms, and over 30% anticipated revenue growth in BioPharma Solutions. Sonexus, its patient support business, has won several manufacturer hub programs, including Sanofi and Regeneron's Dupixent My Way, collectively serving over 1 million patients.

On regulatory matters, Cardinal said it completed the transition of manufacturer distribution service agreements for all branded pharmaceuticals affected by the 2026 Medicare Drug Price Negotiation Program before the January 1 implementation date, and expects to remain appropriately compensated for its distribution role. The release also introduced the ContinuCare Pathway diabetes-supply program, with Publix enrolling about 1,400 pharmacies. The filing is a non-GAAP guidance update rather than a GAAP outlook, and the release notes that excluded items have historically swung EPS materially, so GAAP results may differ significantly from the non-GAAP figures.

02—Key points

Key Highlights

FY2026 non-GAAP diluted EPS guidance raised to at least $10.00, from $9.65–$9.85 previously, a midpoint increase of roughly 2–3%
Specialty revenues expected to exceed $50 billion in FY2026, representing a 16% three-year CAGR
BioPharma Solutions anticipated to grow over 30% in FY2026, led by Sonexus Access and Patient Support wins
Sonexus selected for Sanofi/Regeneron Dupixent My Way and several oncology hub programs, collectively serving over 1 million patients
All branded pharmaceutical manufacturer distribution agreements affected by 2026 IRA Medicare negotiation successfully transitioned before January 1, 2026
ContinuCare Pathway launched in at-Home Solutions; Publix enrolled nearly 1,400 pharmacies, bringing the program to over 11,000 retail and grocery pharmacies
Next detailed update scheduled for the fiscal Q2 2026 earnings call on February 5, 2026

03—Questions

Frequently Asked Questions

Why did Cardinal Health raise its fiscal 2026 EPS outlook?
Management attributes the raise to strong performance and execution across all five operating segments. The new outlook is at least $10.00 non-GAAP diluted EPS, versus the prior $9.65 to $9.85 range. Detailed drivers will be discussed on the February 5, 2026 earnings call.
How significant is the Specialty revenue target?
Cardinal expects Specialty revenues to exceed $50 billion in FY2026, a 16% CAGR over FY24 to FY26 measured from an FY23 baseline. Growth is expected from specialty distribution demand, MSO platform expansion, and BioPharma Solutions, which is projected to grow over 30% in the year.
Did the IRA drug pricing changes disrupt Cardinal's distribution business?
The company says it transitioned manufacturer distribution service agreements for all affected branded pharmaceuticals before the January 1, 2026 effective date. It expects to remain appropriately compensated for its distribution role, though the release does not quantify the financial impact.
Should investors rely on the non-GAAP guidance as a measure of GAAP earnings?
Not directly. Cardinal does not provide GAAP outlook because excluded items such as impairments, acquisition costs, and litigation charges are hard to forecast. Over the past five fiscal years these items moved EPS between $1.79 and $8.44, including a $6.79 goodwill impairment in fiscal 2022, so GAAP results could differ materially from the non-GAAP guidance.

04—Continue

← View all 8-K filings